{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-21-010321","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2021-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.141804+00:00","generated_at":"2026-06-29T01:42:38.712899+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"GT Biopharma files 8-K regarding ESMO 2021 presentation; no financial results disclosed","bullets":["Dr. Jeffrey Miller presented on GT Biopharma's drug candidates at ESMO Congress 2021.","Updated corporate presentation posted to website as of Sept 20, 2021.","No specific clinical data or financial figures included in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-21-010321","json":"https://secwatch.observer/filing/0001654954-21-010321.json","markdown":"https://secwatch.observer/filing/0001654954-21-010321.md","text":"https://secwatch.observer/filing/0001654954-21-010321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000165495421010321/0001654954-21-010321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000165495421010321/gtbp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T01:42:38.712899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}